Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | MMP2 | P08253 | 2/20 | 0.33 |
| ▸ | MMP9 | P14780 | 2/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.31 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.31 |
| ▸ | AOC2 | O75106 | 3/20 | 0.31 |
| ▸ | MAOB | P27338 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3489599 | 0.85 | CA2 (0.37) | CA2ALDH1A1NPSR1TMEM97SIGMAR1 | |
| SCHEMBL1888652 | 0.83 | CA2 (0.39) | CA2ALDH1A1NPSR1TMEM97SIGMAR1 | |
| SCHEMBL9010034 | 0.78 | PTGS2 (0.38) | ALDH1A1HSD17B10 | |
| SCHEMBL4437467 | 0.77 | MAPK14 (0.39) | CA2ALDH1A1TMEM97SIGMAR1MAPK14 | |
| SCHEMBL6041975 | 0.76 | CA2 (0.49) | CA2ALDH1A1NPSR1MMP2MMP9 | |
| SCHEMBL7308600 | 0.75 | CA2 (0.41) | CA2ALDH1A1NPSR1TMEM97SIGMAR1 | |
| SCHEMBL7298938 | 0.75 | CA2 (0.41) | CA2ALDH1A1NPSR1TMEM97SIGMAR1 | |
| SCHEMBL900004 | 0.74 | GAA (0.38) | ALDH1A1KDM4EHPGDTSHRHSD17B10 | |
| SCHEMBL5861877 | 0.73 | AOC2 (0.36) | CA2ALDH1A1AOC2 | |
| SCHEMBL8664631 | 0.73 | AOC2 (0.36) | CA2ALDH1A1AOC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060079533-A1 | Methods of treating alzheimer's disease | NIEMAN JAMES A | 2006-04-13 | — | — | US | disclosed |
| WO-2002076440-A2 | METHODS OF TREATING ALZHEIMER'S DISEASE WITH PIPERIDIN DERIVATES | ELAN PHARMACEUTICALS, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079533-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, PSEN2 | CA2 1585/4885F10 1325/4885ALDH1A1 2504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.